# Remimazolam for Postoperative Atrial Fibrillation

> **NCT05891145** · NA · RECRUITING · sponsor: **Yangzhou University** · enrollment: 50 (estimated)

## Conditions studied

- Coronary Artery Bypass Grafting
- Remimazolam

## Interventions

- **DRUG:** Remimazolam
- **DRUG:** midazolam

## Key facts

- **NCT ID:** NCT05891145
- **Lead sponsor:** Yangzhou University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891145, "Remimazolam for Postoperative Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05891145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*